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Purpose of the study
Study M05-730 was conducted to compare the safety, tol-
erability, pharmacokinetics (PK) and antiviral activity for
once-daily (QD) and twice-daily (BID) lopinavir/ritona-
vir (LPV/r) tablet in antiretroviral-naïve subjects. The LPV/
r QD regimen was shown to be non-inferior to the BID
regimen. This analysis explores the population PK and
pharmacodynamics (PD) of the LPV/r tablets in HIV-
infected subjects.
Methods
A total of 633 subjects (322 QD and 311 BID) were
included in this analysis. Intensive PK samples were
obtained in 69 subjects. Sparse PK was obtained up to 48
weeks (up to five samples) in all subjects. The model-pre-
dicted ritonavir (RTV) PK parameters [apparent clearance
(CL/F), volume of distribution (Vc/F) and absorption rate
constant (ka)] were included in the population PK mode-
ling for lopinavir (LPV). Covariate analysis (age, sex, race,
weight, body surface area, creatinine clearance, dosing
regimen [QD versus BID], hepatitis B/C virus, and alcohol
use) was performed for RTV and LPV to identify potential
covariates that may alter the PK profile. Individual LPV
exposure (maximum concentrations [Cmax], area under
the curve [AUC] and predose trough concentrations
[Cmin]) was estimated. The relationship between these
LPV PK parameters and antiviral efficacy (HIV-1 RNA <50
copies/mL) at week 48 was evaluated using logistic regres-
sion.
Summary of results
Table 1 presents the PK results.
None of the tested covariates had an effect on ritonavir
PK. The only covariate that had an effect on LPV PK was
weight for which a 10-kg increase in weight is estimated to
result in a 4% increase in LPV CL/F. There was no associa-
tion between LPV Cmax, AUC or Cmin vs. virologic effi-
cacy at week 48 (p > 0.1).
Conclusion
In summary, only weight had a small, statistically signifi-
cant but not clinically relevant, effect on LPV CL/F. A pri-
ori adjustment in LPV/r dose based on subject
characteristics (race, sex, weight, renal function, etc.) is
not warranted. The virologic response did not correlate
with LPV levels indicating that, even at the lowest levels
measured in this trial, the virologic response was main-
tained.
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Population Estimate (standard error)
Parameter Ritonavir Lopinavir
CL/F (L/h) 22.79 (0.783) 5.63 (0.11)
Vc/F (L) 244 (20.4) 144 (10.5)
ka (h-1) 0.488 1.22Page 2 of 2
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